Literature DB >> 16487229

When gatekeepers meet the sentinel: the impact of a prior authorization requirement for cefuroxime on the prescribing behaviour of community-based physicians.

Natan R Kahan1, David P Chinitz, Dan-Andrei Waitman, Ernesto Kahan.   

Abstract

AIMS: Prior authorization (PA), the requirement of physicians to obtain pre-approval as a prerequisite for coverage, may decrease drug utilization via a 'sentinel effect', a decrease in utilization caused by external review of prescribing. The purpose of this study was to assess the affect a PA restriction had on the utilization patterns of cefuroxime tablets in a managed care organization (MCO) in Israel.
METHODS: Physician prescribing patterns were evaluated by conducting a retrospective drug utilization analysis. Data were derived from the electronic patient records of the MCO studied. All prescriptions for solid state antibiotics for patients diagnosed with an infectious disease written during three parallel 3-month segments, before, during and after a PA restriction for cefuroxime was enforced, were included. Frequency and proportion of antibiotic prescriptions for cefuroxime tablets, distribution of infectious diseases treated with cefuroxime, and the request rejection rate when PA was required were calculated.
RESULTS: Prescriptions for cefuroxime declined from 5538 prescriptions (8.0% of eligible antibiotic prescriptions, 95% CI 7.8, 8.2) in the initial period to 1036 (1.2%, 95% CI 1.1, 1.3) during the PA period, rising to 3961 (4.3%, 95% CI 4.2, 4.4) in the post-PA period. Changes in the distribution of diseases treated with cefuroxime during the PA stage tended to regress after revocation to those observed in the pre-PA period. The rejection rate was found to be 8.5% (95% CI=6.9, 10.1).
CONCLUSIONS: The implementation of a prior authorization requirement for cefuroxime tablets markedly reduced the use of this drug, probably due to a 'sentinel effect'.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16487229      PMCID: PMC1885015          DOI: 10.1111/j.1365-2125.2006.02577.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Decreasing antibiotic use in ambulatory practice: impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults.

Authors:  R Gonzales; J F Steiner; A Lum; P H Barrett
Journal:  JAMA       Date:  1999-04-28       Impact factor: 56.272

2.  Analysis of a prescription drug prior authorization program in a Medicaid health maintenance organization.

Authors:  Kenneth T LaPensee
Journal:  J Manag Care Pharm       Date:  2003 Jan-Feb

3.  Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors.

Authors:  Michael A Fischer; Sebastian Schneeweiss; Jerry Avorn; Daniel H Solomon
Journal:  N Engl J Med       Date:  2004-11-18       Impact factor: 91.245

4.  Infectious disease--a threat to global health and security.

Authors:  J Lederberg
Journal:  JAMA       Date:  1996-08-07       Impact factor: 56.272

5.  Urinary tract infection in women--physician's preferences for treatment and adherence to guidelines: a national drug utilization study in a managed care setting.

Authors:  Ernesto Kahan; Natan R Kahan; David P Chinitz
Journal:  Eur J Clin Pharmacol       Date:  2003-09-27       Impact factor: 2.953

6.  Physician adherence to recommendations for duration of empiric antibiotic treatment for uncomplicated urinary tract infection in women: a national drug utilization analysis.

Authors:  Natan R Kahan; David P Chinitz; Ernesto Kahan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2004-04       Impact factor: 2.890

7.  Effectiveness of a multiple intervention to reduce antibiotic prescribing for respiratory tract symptoms in primary care: randomised controlled trial.

Authors:  Ineke Welschen; Marijke M Kuyvenhoven; Arno W Hoes; Theo J M Verheij
Journal:  BMJ       Date:  2004-08-05

8.  Educational interventions to improve antibiotic use in the community: report from the International Forum on Antibiotic Resistance (IFAR) colloquium, 2002.

Authors:  Roger G Finch; Joshua P Metlay; Peter G Davey; Lee J Baker
Journal:  Lancet Infect Dis       Date:  2004-01       Impact factor: 25.071

9.  Impact of NSAIDs prior authorization policy on patients' QoL.

Authors:  Aiman A Momani; S Suresh Madhavan; David P Nau
Journal:  Ann Pharmacother       Date:  2002-11       Impact factor: 3.154

10.  A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder.

Authors:  Jeffrey S McCombs; Lizheng Shi; Glen L Stimmel; Thomas W Croghan
Journal:  Clin Ther       Date:  2002-11       Impact factor: 3.393

View more
  8 in total

Review 1.  Impact of pharmaceutical prior authorisation policies : a systematic review of the literature.

Authors:  Jaume Puig-Junoy; Iván Moreno-Torres
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

2.  Revealed Opportunism: How Physicians "Game" Prior Authorization Protocols Until They Are Rescinded.

Authors:  Natan R Kahan; Dan-Andrei Waitman; David P Chinitz
Journal:  Am Health Drug Benefits       Date:  2016-09

Review 3.  Pharmaceutical policies: effects of restrictions on reimbursement.

Authors:  Carolyn J Green; Malcolm Maclure; Patricia M Fortin; Craig R Ramsay; Morten Aaserud; Stan Bardal
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

4.  Variability in outpatient antimicrobial consumption in Israel.

Authors:  O Nitzan; M Low; I Lavi; A Hammerman; S Klang; R Raz
Journal:  Infection       Date:  2010-01-27       Impact factor: 3.553

5.  Evaluating the impact of a novel restricted reimbursement policy for quinolone antibiotics: a time series analysis.

Authors:  Braden Manns; Kevin Laupland; Marcello Tonelli; Song Gao; Brenda Hemmelgarn
Journal:  BMC Health Serv Res       Date:  2012-08-30       Impact factor: 2.655

6.  Impact of a health alert and its implementation on flutamide prescriptions for women: an interrupted time series analysis.

Authors:  Raquel Vázquez-Mourelle; Eduardo Carracedo-Martínez; Adolfo Figueiras
Journal:  BMC Health Serv Res       Date:  2020-06-29       Impact factor: 2.655

7.  Practice characteristics and prior authorization costs: secondary analysis of data collected by SALT-Net in 9 central New York primary care practices.

Authors:  John W Epling; Emily M Mader; Christopher P Morley
Journal:  BMC Health Serv Res       Date:  2014-03-06       Impact factor: 2.655

8.  Ethical Considerations for Equitable Access to Genomic Sequencing for Critically Ill Neonates in the United States.

Authors:  Kristen P Fishler; Joshua C Euteneuer; Luca Brunelli
Journal:  Int J Neonatal Screen       Date:  2022-03-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.